ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism
- PMID: 37500770
- DOI: 10.1038/s41589-023-01391-6
ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism
Abstract
Enolase 1 (ENO1) is a glycolytic enzyme that plays essential roles in various pathological activities including cancer development. However, the mechanisms underlying ENO1-contributed tumorigenesis are not well explained. Here, we uncover that ENO1, as an RNA-binding protein, binds to the cytosine-uracil-guanine-rich elements of YAP1 messenger RNA to promote its translation. ENO1 and YAP1 positively regulate alternative arachidonic acid (AA) metabolism by inverse regulation of PLCB1 and HPGD (15-hydroxyprostaglandin dehydrogenase). The YAP1/PLCB1/HPGD axis-mediated activation of AA metabolism and subsequent accumulation of prostaglandin E2 (PGE2) are responsible for ENO1-mediated cancer progression, which can be retarded by aspirin. Finally, aberrant activation of ENO1/YAP1/PLCB1 and decreased HPGD expression in clinical hepatocellular carcinoma samples indicate a potential correlation between ENO1-regulated AA metabolism and cancer development. These findings underline a new function of ENO1 in regulating AA metabolism and tumorigenesis, suggesting a therapeutic potential for aspirin in patients with liver cancer with aberrant expression of ENO1 or YAP1.
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.
Similar articles
-
Targetting an LncRNA P5848-ENO1 axis inhibits tumor growth in hepatocellular carcinoma.Biosci Rep. 2019 Nov 29;39(11):BSR20180896. doi: 10.1042/BSR20180896. Biosci Rep. 2019. PMID: 30541900 Free PMC article.
-
Enolase-1 is a therapeutic target in endometrial carcinoma.Oncotarget. 2015 Jun 20;6(17):15610-27. doi: 10.18632/oncotarget.3639. Oncotarget. 2015. PMID: 25951350 Free PMC article.
-
Aspirin modulates 2-hydroxyisobutyrylation of ENO1K281 to attenuate the glycolysis and proliferation of hepatoma cells.Biochem Biophys Res Commun. 2021 Jun 30;560:172-178. doi: 10.1016/j.bbrc.2021.04.083. Epub 2021 May 14. Biochem Biophys Res Commun. 2021. PMID: 34000466
-
Enolase 1, a Moonlighting Protein, as a Potential Target for Cancer Treatment.Int J Biol Sci. 2021 Sep 21;17(14):3981-3992. doi: 10.7150/ijbs.63556. eCollection 2021. Int J Biol Sci. 2021. PMID: 34671213 Free PMC article. Review.
-
Alpha-Enolase (ENO1), a potential target in novel immunotherapies.Front Biosci (Landmark Ed). 2017 Jan 1;22(5):944-959. doi: 10.2741/4526. Front Biosci (Landmark Ed). 2017. PMID: 27814656 Review.
Cited by
-
Targeting YAP1 to improve the efficacy of immune checkpoint inhibitors in liver cancer: mechanism and strategy.Front Immunol. 2024 Mar 14;15:1377722. doi: 10.3389/fimmu.2024.1377722. eCollection 2024. Front Immunol. 2024. PMID: 38550587 Free PMC article. Review.
-
Comprehensive assessment of regulatory T-cells-related scoring system for predicting the prognosis, immune microenvironment and therapeutic response in hepatocellular carcinoma.Aging (Albany NY). 2024 Mar 8;16(6):5288-5310. doi: 10.18632/aging.205649. Epub 2024 Mar 8. Aging (Albany NY). 2024. PMID: 38461439 Free PMC article.
References
MeSH terms
Substances
Grants and funding
- 91957203/National Natural Science Foundation of China (National Science Foundation of China)
- 82130087/National Natural Science Foundation of China (National Science Foundation of China)
- 82273221/National Natural Science Foundation of China (National Science Foundation of China)
- 82203556/National Natural Science Foundation of China (National Science Foundation of China)
- 82192893/National Natural Science Foundation of China (National Science Foundation of China)
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous